Financials Dr. Reddy's Laboratories Limited Nyse

Equities

RDY

US2561352038

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-07-16 EDT			5-day change	1st Jan Change
78.47 ^USD	-2.45%		+1.02%	+12.78%

07-16	Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	MT
07-16	Indian Equities Achieve New Closing Highs on Tuesday, Led by Realty, FMCG Goods Stocks	MT

Valuation

Fiscal Period: Marzo	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	516,741	749,317	714,500	767,655	1,024,969	1,106,350	-	-
Enterprise Value (EV) ¹	513,012	745,052	703,980	719,330	960,383	1,017,582	982,385	944,022
P/E ratio	26.6 x	39.2 x	30.4 x	17.1 x	18.4 x	20 x	19.4 x	23 x
Yield	0.8%	0.55%	0.7%	0.87%	0.65%	0.6%	0.61%	0.55%
Capitalization / Revenue	2.96 x	3.95 x	3.33 x	3.11 x	3.66 x	3.66 x	3.4 x	3.44 x
EV / Revenue	2.94 x	3.93 x	3.28 x	2.92 x	3.43 x	3.36 x	3.02 x	2.94 x
EV / EBITDA	11 x	15.7 x	13.7 x	11.1 x	12.1 x	12.1 x	11.2 x	12.3 x
EV / FCF	20.5 x	28.7 x	52.3 x	15.1 x	33.1 x	21.5 x	20.1 x	19.7 x
FCF Yield	4.87%	3.48%	1.91%	6.61%	3.02%	4.64%	4.98%	5.08%
Price to Book	3.33 x	4.29 x	3.76 x	3.33 x	3.63 x	3.4 x	2.95 x	2.64 x
Nbr of stocks (in thousands)	165,776	165,940	165,954	166,105	166,522	166,540	-	-
Reference price ²	3,117	4,516	4,305	4,622	6,155	6,643	6,643	6,643
Announcement Date	20-06-09	21-05-14	22-05-19	23-05-10	24-05-07	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	174,600	189,722	214,391	246,697	280,111	302,427	325,245	321,149
EBITDA ¹	46,431	47,480	51,400	64,559	79,481	84,098	87,464	76,589
EBIT ¹	28,470	31,977	34,277	52,057	64,781	68,756	70,668	59,137
Operating Margin	16.31%	16.85%	15.99%	21.1%	23.13%	22.73%	21.73%	18.41%
Earnings before Tax (EBT) ¹	18,032	28,324	32,298	60,485	72,010	73,804	76,092	63,176
Net income ¹	19,498	19,149	23,568	45,073	55,779	55,128	56,890	48,472
Net margin	11.17%	10.09%	10.99%	18.27%	19.91%	18.23%	17.49%	15.09%
EPS ²	117.4	115.1	141.7	270.9	334.6	332.3	342.8	289.4
Free Cash Flow ¹	24,995	25,962	13,448	47,552	29,030	47,245	48,946	48,001
FCF margin	14.32%	13.68%	6.27%	19.28%	10.36%	15.62%	15.05%	14.95%
FCF Conversion (EBITDA)	53.83%	54.68%	26.16%	73.66%	36.52%	56.18%	55.96%	62.67%
FCF Conversion (Net income)	128.19%	135.58%	57.06%	105.5%	52.04%	85.7%	86.04%	99.03%
Dividend per Share ²	25.00	25.00	30.00	40.00	40.00	39.75	40.20	36.82
Announcement Date	20-06-09	21-05-14	22-05-19	23-05-10	24-05-07	-	-	-

¹INR in Million²INR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Marzo	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	53,197	54,368	52,154	63,057	67,700	63,152	67,384	68,802	72,148	71,138	72,918	75,511	76,562	79,441
EBITDA ¹	12,018	12,980	9,238	18,944	20,562	15,955	20,450	19,915	20,180	18,174	19,854	20,864	20,370	21,246
EBIT ¹	9,042	8,743	6,188	15,818	17,291	12,800	16,867	16,126	16,410	14,497	16,078	16,733	16,502	16,668
Operating Margin	17%	16.08%	11.86%	25.09%	25.54%	20.27%	25.03%	23.44%	22.74%	20.38%	22.05%	22.16%	21.55%	20.98%
Earnings before Tax (EBT) ¹	9,709	2,483	14,655	16,111	16,346	13,291	18,463	19,134	18,257	16,052	17,018	17,634	17,190	17,918
Net income ¹	7,065	875	11,876	11,128	12,471	9,601	14,025	14,800	13,789	13,098	13,182	13,326	12,980	13,550
Net margin	13.28%	1.61%	22.77%	17.65%	18.42%	15.2%	20.81%	21.51%	19.11%	18.41%	18.08%	17.65%	16.95%	17.06%
EPS ²	42.48	5.260	71.40	66.89	74.95	57.68	84.22	88.78	82.68	78.53	79.13	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	22-01-28	22-05-19	22-07-28	22-10-28	23-01-25	23-05-10	23-07-26	23-10-27	24-01-30	24-05-07	-	-	-	-

¹INR in Million²INR

Estimates

Balance Sheet Analysis

Fiscal Period: Marzo	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	3,729	4,265	10,520	48,325	64,586	88,768	123,964	162,328
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	24,995	25,962	13,448	47,552	29,030	47,245	48,946	48,001
ROE (net income / shareholders' equity)	13.2%	11.6%	13%	21.4%	21.6%	17.9%	16%	12.1%
ROA (Net income/ Total Assets)	8.52%	7.69%	8.39%	14.7%	15.7%	12.4%	11.3%	9.54%
Assets ¹	228,823	248,866	281,073	307,340	355,745	444,486	503,468	508,057
Book Value Per Share ²	935.0	1,052	1,145	1,387	1,694	1,955	2,250	2,515
Cash Flow per Share ²	180.0	215.0	169.0	354.0	272.0	404.0	432.0	407.0
Capex ¹	4,846	9,741	14,660	11,323	16,403	18,096	15,989	16,267
Capex / Sales	2.78%	5.13%	6.84%	4.59%	5.86%	5.98%	4.92%	5.07%
Announcement Date	20-06-09	21-05-14	22-05-19	23-05-10	24-05-07	-	-	-

¹INR in Million²INR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,643 INR

Average target price

6,164 INR

Spread / Average Target

-7.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+34.02%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+11.41%	234B
NOVARTIS AG	+15.35%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals